
While demand for prescription stimulants is surging, a shortage of the drugs persists, so federal officials have stepped in and asked drug companies to ramp up production of the medications. Officials from both the U.S. Food and Drug Administration and the U.S. Drug Enforcement Administration (DEA) made the joint request. “The FDA and DEA do not manufacture drugs and cannot require a pharmaceutical company to make a drug, make more of a drug or change the distribution of a drug,” FDA Commissioner Dr. Robert Califf and Drug Enforcement Administration leader Anne Milgram wrote in a letter issued Tuesday. “That said, we are working closely with numerous manufacturers, agencies and others in the supply chain to understand, prevent and reduce the impact of these shortages.” The agencies are also asking prescribers to carefully monitor their prescribing practices. “The lack of availability of certain medications in recent months has been understandably frustrating for patients and their families,” Califf and Milgram wrote in their letter. Reasons for the shortage include manufacturing delays by one drugmaker last fall. Meanwhile, demand for prescription stimulants for adults surged during the pandemic, according to a U.S. Centers for Disease Control and Prevention report. The FDA first announced a shortage of Adderall last October; that medication is commonly used for those with attention deficit hyperactivity disorder (ADHD). The DEA limits the amount of… read on > read on >